Glaucoma Assessment Via Reading Ability

December 30, 2022 updated by: Peking University

Glaucoma Assessment Via Reading Ability Using Logarithmic Chinese Reading Acuity Chart

To explore a quantitative glaucoma evaluation tool of glaucoma through the dynamic evaluation of reading ability based on logarithmic Chinese reading acuity chart (C-READ), and investigate its feasibility.

Study Overview

Status

Not yet recruiting

Intervention / Treatment

Detailed Description

Glaucoma is the most common cause of irreversible blindness in the world, and it's marked by the gradual loss of retinal ganglion cells and their optic nerve fibres. Early detection and treatment can successfully prevent the disease's development and prevent blindness. Glaucoma sufferers' near visual qualities, particularly their ability to read, might be compromised. Patients can, however, regain some comfortable reading capacity following glaucoma therapy. The logarithmic Chinese reading acuity chart (C-READ) can be beneficial as a tool for functional vision evaluation, and there is rising clinical interest in this well-standardized, calibrated reading chart. Reading chart standards that allow for equal assessment of reading factors such as acuity and speed are currently lacking. The C-READ approach as a judge of glaucoma patients' status lacks theoretical support, and functional visual evaluation tools are still in their infancy. Therefore, we want to complete these tasks: 1) develop a dynamic analytic system and improve the evaluation criteria for the C-READ testing procedure; 2) confirm the usefulness of C-READ for early glaucoma screening through clinical studies. C-READ will provide a reliable and cost-effective screening technique that is convenient, affordable, and noninvasive.

Study Type

Observational

Enrollment (Anticipated)

200

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

The patients who were diagnosed as primary open angle glaucoma in the Eye Center of the Third Hospital of Beijing Medical University from January 2023 to December 2023 will be included. At the same time, healthy people will be included as the control group.

Description

Inclusion Criteria:

  • Primary open angle glaucoma in at least 1 eye or labelled as a glaucoma suspect by a glaucoma specialist
  • Age ≥18 years old
  • with open angles on gonioscopy
  • best-corrected visual acuity ≥0.5
  • spherical refraction within ±5.0 diopters (D), and/or cylinder correction within 3.0 D

Exclusion Criteria:

  • eyes with any evidence of physical abnormality of the iris or pupils on slit-lamp examination
  • eyes with a history of trauma or inflammation
  • undergone an intraocular surgery or laser within the previous 6 months/except uncomplicated cataract surgery
  • using systemic or topical medications that could affect pupil responses, including pilocarpine or atropine
  • presence of any media opacities that prevented good quality OCT or fundus images
  • presence of any retinal or neurological disease other than glaucoma
  • abnormal ocular motility that prevents binocular fixation (eg, nystagmus, strabismus)
  • with severe systemic diseases or psychiatric disorders

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Case-Control
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Case group
Patients with primary open angle glaucoma
C-Read is a reliable and valid clinical tool for quantitatively testing the reading ability of readers of simplified Chinese characters.
Control group
Healthy people
C-Read is a reliable and valid clinical tool for quantitatively testing the reading ability of readers of simplified Chinese characters.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The Relationship between Reading Ability and C-READ Test Results
Time Frame: January 2023 to December 2023
The Relationship between Reading Ability and C-READ Test Results
January 2023 to December 2023

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Anticipated)

January 1, 2023

Primary Completion (Anticipated)

December 31, 2023

Study Completion (Anticipated)

February 29, 2024

Study Registration Dates

First Submitted

December 30, 2022

First Submitted That Met QC Criteria

December 30, 2022

First Posted (Estimate)

January 6, 2023

Study Record Updates

Last Update Posted (Estimate)

January 6, 2023

Last Update Submitted That Met QC Criteria

December 30, 2022

Last Verified

December 1, 2022

More Information

Terms related to this study

Other Study ID Numbers

  • IRB00006761-M2022800

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Glaucoma, Primary Open Angle

Clinical Trials on C-Read test

Subscribe